CY2293B1 - Slow-release pharmaceutical formulations containing mizolastin - Google Patents

Slow-release pharmaceutical formulations containing mizolastin

Info

Publication number
CY2293B1
CY2293B1 CY0200052A CY0200052A CY2293B1 CY 2293 B1 CY2293 B1 CY 2293B1 CY 0200052 A CY0200052 A CY 0200052A CY 0200052 A CY0200052 A CY 0200052A CY 2293 B1 CY2293 B1 CY 2293B1
Authority
CY
Cyprus
Prior art keywords
mizolastin
slow
pharmaceutical formulations
formulations containing
release pharmaceutical
Prior art date
Application number
CY0200052A
Other languages
English (en)
Inventor
Maryvonne Chariot
Gareth Lewis
Jean Montel
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of CY2293B1 publication Critical patent/CY2293B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY0200052A 1996-03-04 2002-08-26 Slow-release pharmaceutical formulations containing mizolastin CY2293B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9602662A FR2745500B1 (fr) 1996-03-04 1996-03-04 Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine

Publications (1)

Publication Number Publication Date
CY2293B1 true CY2293B1 (en) 2003-07-04

Family

ID=9489799

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0200052A CY2293B1 (en) 1996-03-04 2002-08-26 Slow-release pharmaceutical formulations containing mizolastin

Country Status (35)

Country Link
US (2) US6165507A (pl)
EP (1) EP0906101B1 (pl)
JP (2) JP2000512617A (pl)
KR (1) KR100369888B1 (pl)
CN (1) CN1112929C (pl)
AR (1) AR006082A1 (pl)
AT (1) ATE219365T1 (pl)
AU (1) AU725494B2 (pl)
BG (1) BG63451B1 (pl)
BR (1) BR9707827A (pl)
CA (1) CA2247405C (pl)
CO (1) CO4780020A1 (pl)
CY (1) CY2293B1 (pl)
CZ (1) CZ291418B6 (pl)
DE (1) DE69713505T2 (pl)
DK (1) DK0906101T3 (pl)
EE (1) EE03511B1 (pl)
ES (1) ES2177942T3 (pl)
FR (1) FR2745500B1 (pl)
HK (1) HK1017999A1 (pl)
HU (1) HU227472B1 (pl)
IL (1) IL126050A (pl)
IN (1) IN187739B (pl)
NO (1) NO315841B1 (pl)
NZ (1) NZ331947A (pl)
OA (1) OA10854A (pl)
PL (1) PL189813B1 (pl)
PT (1) PT906101E (pl)
RU (1) RU2173997C2 (pl)
SK (1) SK282112B6 (pl)
TR (1) TR199801574T2 (pl)
TW (1) TW491711B (pl)
UA (1) UA49004C2 (pl)
WO (1) WO1997032584A1 (pl)
ZA (1) ZA971830B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002087960A (ja) * 2000-07-14 2002-03-27 Toyama Chem Co Ltd 徐放性錠剤
PT1322158E (pt) * 2000-10-02 2012-11-23 Usv Ltd Composições farmacêuticas de libertação prolongada contendo metformina e seu método de produção
US7052706B2 (en) 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
EP1599189A4 (en) * 2003-03-04 2009-07-01 Nostrum Pharmaceuticals Inc FORMULATION WITH CONTROLLED RELEASE AND WITH WATER-REPELLENT MATERIAL AS A MEANS FOR DELAYED RELEASE
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
EA201201451A1 (ru) 2008-07-28 2013-07-30 Такеда Фармасьютикал Компани Лимитед Фармацевтическая композиция
JP5744412B2 (ja) * 2010-03-26 2015-07-08 テバ製薬株式会社 フロセミド製剤
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364945A (en) * 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
FR2587029B1 (fr) * 1985-09-11 1987-10-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
JPH0776172B2 (ja) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
JPS62283926A (ja) * 1986-06-02 1987-12-09 Nippon Chemiphar Co Ltd 塩酸ニカルジピン持続性組成物
DE3812799A1 (de) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
JP3195391B2 (ja) * 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤

Also Published As

Publication number Publication date
JP2000512617A (ja) 2000-09-26
AR006082A1 (es) 1999-08-11
PT906101E (pt) 2002-09-30
ZA971830B (en) 1997-09-04
CO4780020A1 (es) 1999-05-26
FR2745500B1 (fr) 1998-04-03
IL126050A (en) 2004-05-12
TW491711B (en) 2002-06-21
AU1930097A (en) 1997-09-22
BG63451B1 (bg) 2002-02-28
US20050202089A1 (en) 2005-09-15
CA2247405C (en) 2004-04-20
CZ279198A3 (cs) 1999-01-13
US6165507A (en) 2000-12-26
KR19990087387A (ko) 1999-12-27
CA2247405A1 (en) 1997-09-12
DE69713505T2 (de) 2003-02-13
PL189813B1 (pl) 2005-09-30
ES2177942T3 (es) 2002-12-16
DK0906101T3 (da) 2002-10-14
DE69713505D1 (de) 2002-07-25
HU227472B1 (en) 2011-07-28
BG102692A (en) 1999-04-30
NO984035D0 (no) 1998-09-02
EP0906101B1 (fr) 2002-06-19
HUP9902458A3 (en) 2002-11-28
ATE219365T1 (de) 2002-07-15
CN1112929C (zh) 2003-07-02
IN187739B (pl) 2002-06-15
CZ291418B6 (cs) 2003-03-12
NO315841B1 (no) 2003-11-03
HUP9902458A2 (hu) 2000-05-28
JP2007182451A (ja) 2007-07-19
NZ331947A (en) 2000-03-27
KR100369888B1 (ko) 2003-05-17
NO984035L (no) 1998-10-22
PL328763A1 (en) 1999-02-15
AU725494B2 (en) 2000-10-12
BR9707827A (pt) 1999-07-27
SK121098A3 (en) 1999-01-11
SK282112B6 (sk) 2001-11-06
WO1997032584A1 (fr) 1997-09-12
OA10854A (fr) 2003-02-05
IL126050A0 (en) 1999-05-09
HK1017999A1 (en) 1999-12-10
TR199801574T2 (xx) 1998-11-23
EP0906101A1 (fr) 1999-04-07
FR2745500A1 (fr) 1997-09-05
UA49004C2 (uk) 2002-09-16
RU2173997C2 (ru) 2001-09-27
EE03511B1 (et) 2001-10-15
CN1212624A (zh) 1999-03-31
EE9800275A (et) 1999-02-15

Similar Documents

Publication Publication Date Title
EG23826A (en) Pharmaceutical formulations
GB9713149D0 (en) Pharmaceutical formulations
AP9500733A0 (en) Pharmaceutical formulations
GB9523752D0 (en) Pharmaceutical formulations
SG79255A1 (en) Pharmaceutical formulations
GB9404248D0 (en) Pharmaceutical formulations
ZA982872B (en) Pharmaceutical formulation
CY2293B1 (en) Slow-release pharmaceutical formulations containing mizolastin
GB9709739D0 (en) Pharmaceutical formulation
HUP0003528A3 (en) Pharmaceutical compositions containing dihydropolyprenols
ZA96392B (en) Pharmaceutical formulations
SI0906101T1 (en) Slow-release pharmaceutical formulations containing mizolastin
GB9413542D0 (en) Pharmaceutical formulations
GB9500978D0 (en) Pharmaceutical formulations
GB9621531D0 (en) Pharmaceutical formulations
GB9606372D0 (en) Pharmaceutical formulations
GB9703607D0 (en) Pharmaceutical formulations
GB9603141D0 (en) Pharmaceutical formulation
GB9807556D0 (en) Pharmaceutical formulations
GB9805931D0 (en) Pharmaceutical formulations
GB9825117D0 (en) Pharmaceutical formulations
GB9813452D0 (en) Pharmaceutical formulations
GB9817429D0 (en) Pharmaceutical formulations
GB9820837D0 (en) Pharmaceutical formulations
GB9828205D0 (en) Pharmaceutical formulations